Cognition Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $89.4M
- Price
- $0.94
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.20%
- Volume
- 330.5K
About
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
Quick stats
Shares outstanding95.1M
Computed float79.3M
Float / shares83.3%
Cash runway (months)22.2
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001455365
Websitehttps://www.cogrx.com
AI Summary
AI-generated1/13
standardbullishclinical trial
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
Cognition Therapeutics scheduled a Type C meeting with the FDA Division of Neurology for October 20, 2026, to align on the primary endpoint for a planned registrational Phase 3 trial of zervimesine (CT1812) in dementia with Lewy bodies with psychosis.
FDA minutes from June 2026 already supported measuring psychosis as a primary outcome; the Phase 3 will randomize patients to 100 mg once-daily oral zervimesine or placebo for nine months.
The move builds on Phase 2 SHIMMER data showing an 89% slowdown in hallucination and delusion progression versus placebo, though endpoint alignment remains an unresolved regulatory step before the pivotal study can launch.
Red flags
- Endpoint alignment with FDA not yet finalized; meeting outcome is uncertain
- Clinical-stage company dependent on grant funding and capital markets; Nasdaq listing maintenance cited as a risk factor